• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Keywords » Enzyvant Therapeutics Inc.

Items Tagged with 'Enzyvant Therapeutics Inc.'

ARTICLES

Rare disease illustration

Capture ‘hearts and minds,’ says Ovid’s Levin during rare-disease panel

Jan. 12, 2022
By Randy Osborne
Drug sponsors should not focus on influencing legislators about how to price rare-disease and orphan therapies, Ovid Therapeutics Inc. CEO Jeremy Levin said during a panel talk at Biotech Showcase. “The game is not in Washington,” he said. “The game is on the ground in each state, where you need to convince the public, the individuals, the patients that, in fact, you are bringing value.”
Read More

Enzyvant wins FDA approval for congenital athymia therapy Rethymic

Oct. 11, 2021
By Michael Fitzhugh
Nearly two years after confronting an initial complete response letter, Enzyvant Therapeutics Inc. has won FDA approval for a unique treatment for children born without a thymus, an ultra-rare condition leaving them deeply disadvantaged in fighting infections. The product, to be marketed as Rethymic, is the first thymus tissue product approved in the U.S.
Read More

Sumitomo Dainippon strikes rich tie-up with Roivant; shells out $3B for ownership in five 'Vants'

Sep. 11, 2019
By Michael Fitzhugh
Japan's Sumitomo Dainippon Pharma Co. Ltd. plans to pay $3 billion to acquire Roivant Sciences Ltd.'s ownership interests in five biopharma companies, plus options to acquire up to six more from the prolific company-builder. The deal, slated to close in October, would give Sumitomo Dainippon controlling interests in Myovant Sciences Inc., Urovant Sciences Inc., Enzyvant Therapeutics Inc. and Altavant Sciences Inc., as well as an equity stake of more than 10% in Roivant itself.
Read More

Sumitomo Dainippon strikes rich tie-up with Roivant; shells out $3B for ownership stakes in five 'Vants'

Sep. 9, 2019
By Michael Fitzhugh
Japan's Sumitomo Dainippon Pharma Co. Ltd. plans to pay $3 billion to acquire Roivant Sciences Ltd.'s ownership interests in five biopharma companies, plus options to acquire up to six more from the prolific company-builder. The deal, slated to close in October, would give Sumitomo Dainippon controlling interests in Myovant Sciences Inc., Urovant Sciences Inc., Enzyvant Therapeutics Inc. and Altavant Sciences Inc., as well as an equity stake of more than 10% in Roivant itself.
Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 14, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 14, 2025.
  • Scientific figure illustrating astrocytes and neuron synapse

    Glia 2025: Microglial crosstalk could be early Alzheimer’s targeting opportunity

    BioWorld
    “Loss of synapses and dysfunctional synapses in a region-specific way is important in Alzheimer’s. It’s actually the strongest correlate of cognitive decline, far...
  • New oral BRD4 inhibitor blocks pathogenic expansion of epithelial progenitors in IPF models

    BioWorld Science
    Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited treatment options. IPF is thought to result from repeated microinjuries...
  • Merger-arrows-black-white.png

    BD’s biosciences & diagnostics unit in $17.5B merger with Waters

    BioWorld MedTech
    Three months earlier than an expected update on a deal, Becton, Dickinson and Co. reported its biosciences and diagnostic solutions business will combine with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe